{"resourceType":"Evidence","id":"12","meta":{"versionId":"2","lastUpdated":"2026-05-12T10:53:35.904-03:00"},"extension":[{"url":"https://treatments.telix.health/implementationguide/extensions/study-country","valueCodeableConcept":{"coding":[{"system":"https://hl7.org/fhir/ValueSet/country","code":"CN","display":"China"}]}}],"identifier":[{"use":"official","system":"https://interneb.org/global-computable-evidence-identifiers","value":"osteoarthritis-artrodar-pmc9908446"}],"title":"This Evidence resource describes a clinical study evaluating diacerein-based treatment for knee osteoarthritis.","status":"active","date":"2023-01","publisher":"Linca Telecomunicações Ltda","author":[{"name":"Diuary Cordeiro Machado","telecom":[{"system":"email","value":"diuarycm@gmail.com"}]}],"useContext":[{"code":{"system":"https://build.fhir.org/ig/HL7/ebm/en/ValueSet-179431.html","code":"population","display":"Population"},"valueCodeableConcept":{"coding":[{"system":"https://icd.who.int/ct/icd11_mms/en","version":"2026-01","code":"FA01","display":"Osteoarthritis"}]}},{"code":{"system":"https://build.fhir.org/ig/HL7/ebm/en/ValueSet-179431.html","code":"intervention","display":"Intervention"},"valueCodeableConcept":{"coding":[{"system":"https://www.gs1.org/industries/healthcare","code":"7896281152018","display":"Artrodar 50 mg, 30 capsules, Brazil"}]}},{"code":{"system":"https://build.fhir.org/ig/HL7/ebm/en/ValueSet-179431.html","code":"outcome-measure","display":"Outcome Measure"},"valueCodeableConcept":{"coding":[{"system":"https://terminology.hl7.org/7.1.0/en/ValueSet-research-study-purpose-type.html","code":"efficacy","display":"Efficacy Study"}]}}],"relatedArtifact":[{"type":"citation","display":"Zhiyu Wang et al. American Journal of Translational Research, 01 / 2023","document":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9908446/","title":"Diacerein plus glucosamine hydrochloride improves the safety and efficacy and inhibit inflammatory factors in the treatment of knee osteoarthritis"}}],"variableDefinition":[{"description":"Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.","variableRole":{"coding":[{"system":"https://www.hl7.org/fhir/valueset-variable-role.html","code":"measuredVariable","display":"Measured Variable"}]}}],"studyDesign":[{"coding":[{"system":"https://hl7.org/fhir/codesystem-study-design.html","code":"SEVCO:010013","display":"Case-control studies"}]}],"statistic":[{"description":"Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.","category":{"coding":[{"system":"https://treatments.telix.health/codesystem/categorized-efficacy-outcomes","code":"persistent-reduction","display":"Persistent reduction of symptoms/indicators"}]},"numberOfEvents":55,"numberAffected":35,"sampleSize":{"numberOfParticipants":116}}]}